Cargando…

Pregnancy, sex and hormonal factors in multiple sclerosis

BACKGROUND: Multiple sclerosis (MS) is influenced by pregnancy, sex and hormonal factors. OBJECTIVES: A comprehensive understanding of the role of pregnancy, sex and hormonal factors can provide insights into disease mechanisms, and new therapeutic developments and can provide improved patient care...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, David H, Fazekas, Franz, Montalban, Xavier, Reingold, Stephen C, Trojano, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2014
Materias:	Topical Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458871/ https://www.ncbi.nlm.nih.gov/pubmed/24446387 http://dx.doi.org/10.1177/1352458513519840

Ejemplares similares

The Multiple Sclerosis Care Unit
por: Soelberg Sorensen, Per, et al.
Publicado: (2018)

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis
por: Arnason, Barry G, et al.
Publicado: (2013)

The challenge of comorbidity in clinical trials for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Decentralised clinical trials in multiple sclerosis research
por: Garjani, Afagh, et al.
Publicado: (2022)

Recommendations for observational studies of comorbidity in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

A systematic review of the incidence and prevalence of cancer in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success
por: Marck, Claudia H, et al.
Publicado: (2019)

Neuromodulation for functional bladder disorders in patients with multiple sclerosis
por: Rahnama’i, Mohammad Sajjad
Publicado: (2019)

In vivo imaging of chronic active lesions in multiple sclerosis
por: Calvi, Alberto, et al.
Publicado: (2020)

Is Clostridium perfringens epsilon toxin associated with multiple sclerosis?
por: Titball, Richard W, et al.
Publicado: (2023)

Vision and vision-related outcome measures in multiple sclerosis
por: Balcer, Laura J., et al.
Publicado: (2015)

Environmental Factors and Their Regulation of Immunity in Multiple Sclerosis
por: Trojano, M., et al.
Publicado: (2016)

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
por: Bennett, JL, et al.
Publicado: (2015)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

What’s in a name? That which we call Multiple Sclerosis Fatigue
por: Hubbard, Amy Lynn, et al.
Publicado: (2020)

Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects
por: Olbert, Elisabeth, et al.
Publicado: (2022)

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Analysis of Austrian COVID-19 deaths by age and sex
por: Posch, Martin, et al.
Publicado: (2020)

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2017)

Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review
por: Alexander, Sarah, et al.
Publicado: (2020)

The relation between peptide hormones and sex hormone in patients with multiple sclerosis
por: Eftekhari, Elham, et al.
Publicado: (2013)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review
por: Karim, Mohammad Ehsanul, et al.
Publicado: (2020)

Multiple sclerosis and nutrition: back to the future?
por: Gold, Ralf, et al.
Publicado: (2020)

Viral etiology of multiple sclerosis: where does the truth lie?
por: Waksman, Byron H., et al.
Publicado: (1986)

Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years
por: Hawton, Annie, et al.
Publicado: (2020)

Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care
por: Saposnik, Gustavo, et al.
Publicado: (2018)

Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms
por: Heitmann, Henrik, et al.
Publicado: (2020)

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
por: Reder, Anthony T, et al.
Publicado: (2022)

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity
por: Hegen, Harald, et al.
Publicado: (2022)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
por: Fazekas, Franz
Publicado: (2012)

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bir1ugth59gfgsafab8ttu4dnb